Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.40 |
| ▸ | NQO2 | P16083 | 1/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8055181 | 0.86 | TDP1 (0.35) | EGLN1PDK2TDP1 | |
| SCHEMBL3608280 | 0.80 | EGLN1 (0.42) | EGLN1NQO2 | |
| SCHEMBL16247844 | 0.79 | ALDH1A1 (0.35) | NQO2 | |
| SCHEMBL10376639 | 0.72 | LMNA (0.50) | PDK2TDP1 | |
| SCHEMBL31347383 | 0.72 | EGLN1 (0.38) | EGLN1NQO2 | |
| SCHEMBL1830615 | 0.72 | PDE10A (0.37) | PDK2TDP1 | |
| SCHEMBL4446227 | 0.69 | ALDH1A1 (0.41) | NQO2 | |
| SCHEMBL15055302 | 0.68 | LMNA (0.37) | PDK2TDP1 | |
| SCHEMBL22655948 | 0.68 | TDP1 (0.31) | TDP1 | |
| SCHEMBL10813311 | 0.68 | PDE10A (0.34) | PDK2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156811-A1 | Process for the Preparation of Bosentan | DIPHARMA FRANCIS S.R.L. (IT) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156811-A1 | Process for the Preparation of Bosentan | PAH, HBB, HBZ | EGLN1 314/4885NQO2 2698/4885PDK2 3614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.